Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Novel agents for metastatic hormone-sensitive prostate cancer - a practice guide for urologists.

Thangasamy IA, Kwan EM, Teh J, Sathianathen N, Alghazo O, Siva S, Azad A, Murphy DG.

BJU Int. 2019 Oct 29. doi: 10.1111/bju.14936. [Epub ahead of print] No abstract available.

PMID:
31660679
2.

Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.

Shiota M, Eto M.

Int J Urol. 2016 May;23(5):360-9. doi: 10.1111/iju.13091. Epub 2016 Apr 8. Review.

3.

Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.

Damodaran S, Lang JM, Jarrard DF.

J Urol. 2019 May;201(5):876-885. doi: 10.1097/JU.0000000000000117. Review.

PMID:
30747897
4.

Taxane-based Combination Therapies for Metastatic Prostate Cancer.

Corn PG, Agarwal N, Araujo JC, Sonpavde G.

Eur Urol Focus. 2019 May;5(3):369-380. doi: 10.1016/j.euf.2017.11.009. Epub 2017 Dec 21. Review.

PMID:
29275145
5.

Emerging Therapies in Metastatic Prostate Cancer.

Sonnenburg DW, Morgans AK.

Curr Oncol Rep. 2018 Apr 11;20(6):46. doi: 10.1007/s11912-018-0692-z. Review.

PMID:
29644451
6.

[Chemotherapy combined with androgen-deprivation therapy in high-volume metastatic hormone sensitive prostate cancer: a short-term efficacy and safety analysis].

Xu PH, Shen YJ, Xiao WJ, Lin GW, Qin XJ, Zhu Y, Dai B, Ye DW.

Zhonghua Wai Ke Za Zhi. 2019 Jun 1;57(6):418-421. doi: 10.3760/cma.j.issn.0529-5815.2019.06.005. Chinese.

PMID:
31142065
7.

Austrian recommendations on Targeted Hormone Therapy for metastatic, castration-resistant prostate cancer.

Ponholzer A, Loidl W, Bektic J, Dorfinger K, Hruby S, Jeschke K, Kramer G, Krause S, Ludvik G, Remzi M, Roider M, Stoiber F.

Wien Klin Wochenschr. 2016 Feb;128(3-4):156-63. doi: 10.1007/s00508-015-0945-x. Epub 2016 Feb 1.

PMID:
26831188
8.

Therapies used in prostate cancer patients by European urologists: data on indication with a focus on expectations, perceived barriers and guideline compliance related to the use of bisphosphonates.

Heidenreich A, Witjes WP, Bjerklund-Johansen TE, Patel A; EAU Research Foundation.

Urol Int. 2012;89(1):30-8. doi: 10.1159/000338810. Epub 2012 Jun 13.

PMID:
22699678
9.
10.

Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.

Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP.

J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Epub 2015 Jul 18. Review.

PMID:
26196735
11.

Health Care Delivery for Metastatic Hormone-sensitive Prostate Cancer Across the Globe.

Herlemann A, Washington SL 3rd, Cooperberg MR.

Eur Urol Focus. 2019 Mar;5(2):155-158. doi: 10.1016/j.euf.2018.12.003. Epub 2018 Dec 23. Review.

PMID:
30587443
12.

Early Docetaxel and Androgen Deprivation in the Treatment of Metastatic, Hormone-sensitive Prostate Cancer.

Tassinari D, Tamburini E, Gianni L, Drudi F, Fantini M, Santelmo C, Stocchi L, Montanari F, Sartori S.

Rev Recent Clin Trials. 2016;11(4):317-323. Review.

PMID:
27448518
13.

Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis.

Sathianathen NJ, Koschel S, Thangasamy IA, Teh J, Alghazo O, Butcher G, Howard H, Kapoor J, Lawrentschuk N, Siva S, Azad A, Tran B, Bolton D, Murphy DG.

Eur Urol. 2019 Oct 31. pii: S0302-2838(19)30693-1. doi: 10.1016/j.eururo.2019.09.004. [Epub ahead of print] Review.

PMID:
31679970
14.

Intermittent androgen deprivation therapy in advanced prostate cancer.

Alva A, Hussain M.

Curr Treat Options Oncol. 2014 Mar;15(1):127-36. doi: 10.1007/s11864-013-0272-2. Review.

PMID:
24395278
15.

Novel androgen axis systemic therapies for metastatic hormone-sensitive prostate cancer.

Hahn AW, Hale P, Rathi N, Agarwal N.

Curr Opin Urol. 2017 Nov;27(6):559-565. doi: 10.1097/MOU.0000000000000443. Review.

PMID:
28816716
16.

Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer.

Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS.

J Clin Oncol. 2007 Dec 1;25(34):5359-65.

17.

The biology of hormone refractory prostate cancer. Why does it develop?

Isaacs JT.

Urol Clin North Am. 1999 May;26(2):263-73. Review.

PMID:
10361549
18.

Early use of chemotherapy in metastatic prostate cancer.

Markowski MC, Carducci MA.

Cancer Treat Rev. 2017 Apr;55:218-224. doi: 10.1016/j.ctrv.2016.09.017. Epub 2016 Oct 3. Review.

PMID:
27720577
19.

Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.

Tucci M, Bertaglia V, Vignani F, Buttigliero C, Fiori C, Porpiglia F, Scagliotti GV, Di Maio M.

Eur Urol. 2016 Apr;69(4):563-573. doi: 10.1016/j.eururo.2015.09.013. Epub 2015 Sep 28. Review.

20.

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.

Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES.

Eur Urol. 2019 Jan;75(1):88-99. doi: 10.1016/j.eururo.2018.03.028. Epub 2018 Apr 16. Review.

PMID:
29673712

Supplemental Content

Support Center